P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Contacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager


Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints


Recent Issues

October 2009

Features

Health Care and Law

Should Your Genes Be Subject to Patents?

No, Says a New ACLU Lawsuit

The American Civil Liberties Union is suing Myriad Genetics, a company whose patents protect information about genes linked to breast and ovarian cancer. The status of gene patents may be changing in an age where patients are able to sequence their own DNA and our knowledge about the human genome is expanding more rapidly than ever.
Robert I. Field, JD, MPH, PhD

Drug Utilization Evaluation

Prescribing Trends with Levalbuterol (Xopenex) at a Community Hospital

The authors sought to determine whether levalbuterol use was in compliance with P&T committee–approved guidelines. Removing levalbuterol from the formulary resulted in cost savings and did not result in any lack of therapeutic benefit.
Nicole D. Verkleeren, PharmD, BCPS, and Krista M. Lipchick, PharmD

Drug Review

Erlotinib (Tarceva) for the Treatment of Non–Small-Cell Lung Cancer and Pancreatic Cancer

Erlotinib appears to improve survival for patients with advanced lung cancer who have not responded to chemotherapy. It is also the first therapy in more than a decade that may prolong survival in patients with advanced pancreatic cancer.
Caio M. Rocha-Lima, MD, and Luis E. Raez, MD

Meeting Highlights

European Society of Cardiology, 2009 Congress and A Comparison of Two Asthma Medications

At this international cardiology meeting, studies focused on dabigatran (Pradaxa), a promising substitute for warfarin; ticagrelor (Brilinta), a platelet inhibitor; otamixaban, an anticoagulant; and ezetimibe/atorvastatin (Vytorin) for reducing cholesterol levels and other cardiac risk factors. A comparison of beclomethasone-HFA (Qvar) and fluticasone (Flovent) for asthma is also presented.
Walter Alexander

Pharmaceutical Approval Update

Topics include asenapine sublingual tablets (Saphris) for schizophrenia and bipolar disorder; saxagliptin (Onglyza) for obtaining glucose control in type-2 diabetes; and interferon beta-1b (Extavia) injection for patents with multiple sclerosis.
Marvin M. Goldenberg, PhD, RPh, MS

Departments

Editorial

My Dad

David B. Nash, MD, MBA, pays tribute to his father and provides a first-hand account of some problems with ­hospitals in the U.S.
David B. Nash, MD, MBA

Medication Errors

Paralyzed by Mistakes, Part 2

Preventing Errors with Neuromuscular Blocking Agents

In Part 2 of a two-part series, Matthew Grissinger, RPh, FASCP, discusses recommendations for avoiding mistakes when using neuromuscular blocking agents.
Matthew Grissinger, RPh, FASCP

Prescription: Washington

FDA Opens Door a Sliver to Gain Access to Investigational Drugs

New Policy’s Success Depends on Manufacturers

Stephen Barlas discusses the FDA’s position on greater availability of experimental drugs for critically ill patients.
Stephen Barlas

New Drugs/Drug News/New Medical Devices

From Intuniv to Valturna, P&T presents the latest studies and information about FDA approvals, recalls, and industry updates.

Drug Forecast

Tolvaptan (Samsca) for Hyponatremia: Is It Worth Its Salt?

Authors Reilly and Chavez re­view tolvaptan (Samsca) for patients with hyponatremia.
Timothy Reilly, PharmD, BCPS, and Benjamin Chavez, PharmD, BCPP